AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31014423 — intervention group
Group type: COMPARATOR
Intervention: conventional treatment
Number of subjects: 208
Study 28244416 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (40 mg/m2)
Number of subjects: 39
Study 28244416 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (40 mg/m2) plus gemcitabine (50‐125 mg/m2) (C/G)
Number of subjects: 39
Study 28244416 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 39
Study 25542343 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy adapted for health anxiety (delivered by nurses)
Number of subjects: 444
Study 25542343 — intervention group
Group type: COMPARATOR
Intervention: Standard care (delivered by naive therapists)
Number of subjects: 444
Study 23984312 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (BEC) 2.5 mg, initially 1 tablet with subsequent increase to three times a day
Number of subjects: 28
Study 23984312 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO), initially 1 tablet with subsequent increase to three times a day
Number of subjects: 28
Study 21869699 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 2.5 mg/d plus sertraline 50 mg/d
Number of subjects: 41
Study 21869699 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus sertraline 50 mg/d
Number of subjects: 41
Study 19424038 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin (TMG)
Number of subjects: 278
Study 19424038 — intervention group
Group type: COMPARATOR
Intervention: Basiliximab (BAS)
Number of subjects: 278
Study 17763106 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted self-help (manual + videotape + two supportive phone calls)
Number of subjects: 1069
Study 17763106 — intervention group
Group type: COMPARATOR
Intervention: Manual only (self-help manual)
Number of subjects: 1069
Study 17763106 — intervention group
Group type: COMPARATOR
Intervention: Quitting on one's own (no intervention)
Number of subjects: 1069
Study 15194981 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel with loading dose
Number of subjects: 2962
Study 15194981 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel without loading dose
Number of subjects: 2962
Study 15194981 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (overall)
Number of subjects: 2962
Study 15194981 — intervention group
Group type: EXPERIMENTAL
Intervention: Death or non-fatal myocardial infarction
Number of subjects: 2962
Study 15381441 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy with a body exposure component (CBT-E)
Number of subjects: 28
Study 15381441 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioural therapy with a cognitive restructuring component focused on body image (CBT-C)
Number of subjects: 28
Study 10968328 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg orally, once daily)
Number of subjects: 12
Study 10968328 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin (500 mg orally, twice daily)
Number of subjects: 12
Study 9050956 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intrathecal baclofen infusion (CIBI)
Number of subjects: 18
Study 8378900 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose Curosurf (200 mg/kg initial dose, up to five doses)
Number of subjects: 43
Study 8378900 — intervention group
Group type: COMPARATOR
Intervention: Low dose Curosurf (100 mg/kg initial dose, up to three doses)
Number of subjects: 43
Study 8378900 — intervention group
Group type: EXPERIMENTAL
Intervention: Babies with birthweight < 750 grams or gestational age < 26 weeks
Number of subjects: 43
Study 3718621 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC (tetracaine, adrenaline, and cocaine)
Number of subjects: 68
Study 3718621 — intervention group
Group type: COMPARATOR
Intervention: Tetracaine
Number of subjects: 68
Study 29587530 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep problems
Number of subjects: 240
Study 29335791 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (30 mg total dose, perioperatively)
Number of subjects: 73
Study 29335791 — intervention group
Group type: COMPARATOR
Intervention: Control group (no glucocorticoid)
Number of subjects: 73
Study 27595690 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical activity (PA) intervention for 1 year
Number of subjects: 307
Study 27595690 — intervention group
Group type: COMPARATOR
Intervention: Health education control for 1 year
Number of subjects: 307
Study 27595690 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical activity (PA) intervention
Number of subjects: 307
Study 27595690 — intervention group
Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 307
Study 25128485 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal self-administration of unfractionated heparin (UFH) 7500 IU twice-daily
Number of subjects: 32
Study 25128485 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 32
Study 23247713 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 d of GTE ingestion (GTE1)
Number of subjects: 31
Study 23247713 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 d of GTE ingestion (GTE7)
Number of subjects: 31
Study 23247713 — intervention group
Group type: COMPARATOR
Intervention: Placebo (7 d)
Number of subjects: 31
Study 23247713 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (6 d) followed by 1 d of GTE (GTE1)
Number of subjects: 31
Study 21436923 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Therapy Management (MTM) services provided by third-year pharmacy students
Number of subjects: 0
Study 18841288 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban (bolus of 10 microg/kg body weight followed by continued infusion of 0.15 microg/kg body weight per minute)
Number of subjects: 100
Study 18841288 — intervention group
Group type: COMPARATOR
Intervention: 600 mg clopidogrel and acetylsalicylic acid (ASA)
Number of subjects: 100
Study 17126650 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg 2 times daily)
Number of subjects: 50
Study 17126650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 12792289 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavones (110 mg total per day)
Number of subjects: 56
Study 12792289 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inert ingredients)
Number of subjects: 56
Study 10320160 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive insulin therapy (AIT)
Number of subjects: 26
Study 10320160 — intervention group
Group type: COMPARATOR
Intervention: Standard insulin therapy (SIT)
Number of subjects: 26
Study 9499812 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin during upper respiratory infection (URI)
Number of subjects: 31
Study 9499812 — intervention group
Group type: COMPARATOR
Intervention: Control group (26 subjects without URI)
Number of subjects: 31
Study 1838916 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 10 mg
Number of subjects: 14
Study 1838916 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 10 mg + Hydrochlorothiazide
Number of subjects: 14
Study 1838916 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 14
Study 1838916 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril + Hydrochlorothiazide
Number of subjects: 14
Study 1838916 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 14
Study 6842002 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective antimicrobial modulation (SAM) regimen
Number of subjects: 33
Study 6842002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 30908852 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo fluorescence confocal microscopy (FCM)
Number of subjects: 13
Study 30908852 — intervention group
Group type: COMPARATOR
Intervention: Histopathological diagnoses (gold standard)
Number of subjects: 13
Study 28213566 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavrilimumab 150 mg
Number of subjects: 326
Study 28213566 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavrilimumab 100 mg
Number of subjects: 326
Study 28213566 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavrilimumab 30 mg
Number of subjects: 326
Study 28213566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326
Study 25643304 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-dense, protein-rich oral formula enriched with arginine, zinc, and antioxidants (400 mL/d)
Number of subjects: 200
Study 25643304 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric, isonitrogenous formula
Number of subjects: 200
Study 24004451 — intervention group
Group type: EXPERIMENTAL
Intervention: Yukmijihwang-tang administered for 8 weeks
Number of subjects: 96
Study 24004451 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered for 8 weeks
Number of subjects: 96
Study 21880799 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose daily oral E(2) (0.5 mg)
Number of subjects: 30
Study 21880799 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose transdermal E(2) (0.0375 mg)
Number of subjects: 30
Study 21880799 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral E(2) (2.0 mg)
Number of subjects: 30
Study 21880799 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose transdermal E(2) (0.075 mg)
Number of subjects: 30
Study 21880799 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal E(2)
Number of subjects: 30
Study 21880799 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral E(2) (low or high dose)
Number of subjects: 30
Study 21880799 — intervention group
Group type: EXPERIMENTAL
Intervention: LH and FSH
Number of subjects: 30
Study 21880799 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-I concentrations
Number of subjects: 30
Study 21880799 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein/high-density lipoprotein cholesterol responses
Number of subjects: 30
Study 18854202 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) practice, immediate start
Number of subjects: 50
Study 18854202 — intervention group
Group type: COMPARATOR
Intervention: Transcendental Meditation (TM) practice, delayed start
Number of subjects: 50
Study 17638595 — intervention group
Group type: EXPERIMENTAL
Intervention: autoCPAP devices
Number of subjects: 83
Study 17638595 — intervention group
Group type: COMPARATOR
Intervention: fixed pressure CPAP
Number of subjects: 83
Study 15170933 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Osteoarthritis Test (COAT)
Number of subjects: 125
Study 15170933 — intervention group
Group type: COMPARATOR
Intervention: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Number of subjects: 125
Study 12077039 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP assay in the general population (population screen)
Number of subjects: 591
Study 12077039 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP assay in patients from the three other populations screened
Number of subjects: 591
Study 9804601 — intervention group
Group type: EXPERIMENTAL
Intervention: PSV (Pressure Support Ventilation)
Number of subjects: 12
Study 9804601 — intervention group
Group type: EXPERIMENTAL
Intervention: PAV (Proportional Assist Ventilation)
Number of subjects: 12
Study 10155734 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of immunosuppressive drugs and therapeutic plasma exchange (TPE)
Number of subjects: 24
Study 10155734 — intervention group
Group type: COMPARATOR
Intervention: Immunosuppressive drugs only (Control)
Number of subjects: 24
Study 2521184 — intervention group
Group type: EXPERIMENTAL
Intervention: GR38032F 0.18 mg/kg every 2 hours (trial 1)
Number of subjects: 40
Study 2521184 — intervention group
Group type: EXPERIMENTAL
Intervention: GR38032F 0.04 mg/kg every 2 hours (trial 2)
Number of subjects: 40
Study 2521184 — intervention group
Group type: EXPERIMENTAL
Intervention: GR38032F 0.15 mg/kg every 2 hours (trial 3)
Number of subjects: 40
Study 630905 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% miconazole cream
Number of subjects: 50
Study 630905 — intervention group
Group type: COMPARATOR
Intervention: nystatin pessaries
Number of subjects: 50
Study 6127970 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular dihydrocodeine
Number of subjects: 181
Study 6127970 — intervention group
Group type: COMPARATOR
Intervention: Caudal bupivacaine
Number of subjects: 181
Study 31260792 — intervention group
Group type: EXPERIMENTAL
Intervention: iChoose
Number of subjects: 0
Study 31260792 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Connections
Number of subjects: 0
Study 31260792 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29708766 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined MTrP therapy and stretching plus suboccipital soft tissue inhibition
Number of subjects: 46
Study 29708766 — intervention group
Group type: COMPARATOR
Intervention: Combined MTrP therapy and stretching (control group)
Number of subjects: 46
Study 26644304 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity functional exercise program
Number of subjects: 186
Study 26644304 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control activity
Number of subjects: 186
Study 24874285 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment change (start or change of adjuvant endocrine agent)
Number of subjects: 85
Study 24874285 — intervention group
Group type: COMPARATOR
Intervention: No change (control)
Number of subjects: 85
Study 22230143 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT)
Number of subjects: 200
Study 22230143 — intervention group
Group type: COMPARATOR
Intervention: Non-IPT (control group)
Number of subjects: 200
Study 22230143 — intervention group
Group type: EXPERIMENTAL
Intervention: IPT
Number of subjects: 200
Study 20845089 — intervention group
Group type: EXPERIMENTAL
Intervention: Developed morphine sulfate sustained-release tablets
Number of subjects: 15
Study 20845089 — intervention group
Group type: COMPARATOR
Intervention: Commercial brand of morphine sulfate sustained-release tablets
Number of subjects: 15
Study 17716287 — intervention group
Group type: EXPERIMENTAL
Intervention: Dardia Lipo Line (Intendis GmbH, Berlin, Germany)
Number of subjects: 0
Study 15217841 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly home visits by community health aides for one year in addition to usual duties
Number of subjects: 139
Study 15217841 — intervention group
Group type: COMPARATOR
Intervention: Usual duties
Number of subjects: 139
Study 11515711 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin formulation 1 (250 mg)
Number of subjects: 24
Study 11515711 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin formulation 2 (250 mg)
Number of subjects: 24
Study 11515711 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin formulation 1 and 2
Number of subjects: 24
Study 9061169 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic human bone grafts
Number of subjects: 21
Study 8113479 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-limited psychodynamically oriented treatments (12 sessions)
Number of subjects: 30
Study 8113479 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-unlimited psychodynamically oriented treatments
Number of subjects: 30
Study 8113479 — intervention group
Group type: COMPARATOR
Intervention: Minimal-contact control group
Number of subjects: 30
Study 3533834 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (100 micrograms)
Number of subjects: 0
Study 3533834 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (7.5 mg)
Number of subjects: 0
Study 3533834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28074672 — intervention group
Group type: EXPERIMENTAL
Intervention: Power-assisted exercise intervention (three times a week for thirty minutes over a twenty-week period)
Number of subjects: 37
Study 28074672 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 37
Study 26253730 — intervention group
Group type: EXPERIMENTAL
Intervention: Prandial Technosphere inhaled insulin (TI)
Number of subjects: 353
Study 26253730 — intervention group
Group type: COMPARATOR
Intervention: Prandial Technosphere inhaled placebo (TP)
Number of subjects: 353
Study 25612894 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg/d)
Number of subjects: 19
Study 25612894 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (200 mg/d)
Number of subjects: 19
Study 25612894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 21602259 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 46
Study 21602259 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + fenofibrate
Number of subjects: 46
Study 21602259 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + rimonabant
Number of subjects: 46
Study 18775050 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (ablation)
Number of subjects: 70
Study 18775050 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy (ADT)
Number of subjects: 70
Study 17576402 — intervention group
Group type: EXPERIMENTAL
Intervention: Misgav Ladach method
Number of subjects: 111
Study 17576402 — intervention group
Group type: COMPARATOR
Intervention: Pfannenstiel method
Number of subjects: 111
Study 15274068 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (home-based, moderate-intensity walking)
Number of subjects: 66
Study 15274068 — intervention group
Group type: COMPARATOR
Intervention: Control group (advice to rest)
Number of subjects: 66
Study 11285152 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-day parenteral beta-lactam therapy
Number of subjects: 154
Study 11285152 — intervention group
Group type: COMPARATOR
Intervention: 7-day parenteral beta-lactam therapy
Number of subjects: 154
Study 11285152 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 154
Study 9483391 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (loading dose 10 mg/kg followed by 5 mg/kg/day)
Number of subjects: 53
Study 9483391 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (loading dose 4 mg/kg followed by 4 mg/kg/day)
Number of subjects: 53
Study 9483391 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 53
Study 9483391 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 53
Study 8148229 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 192605 (100 mg)
Number of subjects: 8
Study 8148229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8148229 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 8
Study 3162905 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin (single dose or three divided doses)
Number of subjects: 27
Study 31235709 — intervention group
Group type: EXPERIMENTAL
Intervention: Su-Wang technique (S-W)
Number of subjects: 42
Study 31235709 — intervention group
Group type: COMPARATOR
Intervention: Jaboulay's procedure (JA)
Number of subjects: 42
Study 27720917 — intervention group
Group type: EXPERIMENTAL
Intervention: THC tablet (3 mg 3 times daily for 5 days, then 5 mg 3 times daily for 5 days, followed by 8 mg 3 times daily until days 50-52)
Number of subjects: 65
Study 27720917 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 65
Study 25025548 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-min MDI video
Number of subjects: 91
Study 25025548 — intervention group
Group type: COMPARATOR
Intervention: Nutrition video (control group)
Number of subjects: 91
Study 23363480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation program focusing on learning about brain functions and influences on cognition
Number of subjects: 100
Study 23363480 — intervention group
Group type: COMPARATOR
Intervention: Cognitive rehabilitation program adopting a top-down approach to improve abstract reasoning abilities
Number of subjects: 100
Study 21875845 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidant coping style
Number of subjects: 105
Study 21875845 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-focused coping style
Number of subjects: 105
Study 21875845 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental coping style
Number of subjects: 105
Study 21875845 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic graft-versus-host disease
Number of subjects: 105
Study 21875845 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing symptoms
Number of subjects: 105
Study 19369445 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-collected glans swab specimens (method 1 and method 2)
Number of subjects: 882
Study 19369445 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-collected rectal swab specimens
Number of subjects: 882
Study 19369445 — intervention group
Group type: COMPARATOR
Intervention: Clinician-collected rectal swab specimens
Number of subjects: 882
Study 19369445 — intervention group
Group type: EXPERIMENTAL
Intervention: AC2 and SDA tests
Number of subjects: 882
Study 17462550 — intervention group
Group type: EXPERIMENTAL
Intervention: SVLPD (0.3 g/kg/d of vegetable proteins and ketoanalogues, 1 capsule for every 5 kg of ideal body weight per day)
Number of subjects: 53
Study 17462550 — intervention group
Group type: COMPARATOR
Intervention: Conventional low mixed protein diet (0.6 g/kg/d)
Number of subjects: 53
Study 17462550 — intervention group
Group type: EXPERIMENTAL
Intervention: SVLPD
Number of subjects: 53
Study 17462550 — intervention group
Group type: COMPARATOR
Intervention: Conventional low mixed protein diet
Number of subjects: 53
Study 15466617 — intervention group
Group type: EXPERIMENTAL
Intervention: Turkish version of the Exercise of Self-Care Agency Scale (ESCA)
Number of subjects: 119
Study 15466617 — intervention group
Group type: COMPARATOR
Intervention: English version of the Exercise of Self-Care Agency Scale (ESCA)
Number of subjects: 119
Study 11562580 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated extracorporeal circulation with full dose systemic heparinization (Group B)
Number of subjects: 119
Study 11562580 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated extracorporeal circulation with low dose systemic heparinization (Group C)
Number of subjects: 119